

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

INCREASE IN TOTAL INVESTMENT AND REGISTERED CAPITAL OF A WHOLLY-OWNED SUBSIDIARY

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 8 May 2013, resolutions were passed by the board of directors of Zhuhai Essex, an indirect wholly-owned subsidiary of the Company, approving, among other matters, the increase in the total investment of Zhuhai Essex from RMB28,000,000 (equivalent to approximately HK\$35,000,000) to RMB70,000,000 (equivalent to approximately HK\$87,500,000) and the increase in the registered capital of Zhuhai Essex from RMB20,000,000 (equivalent to approximately HK\$25,000,000) to RMB50,000,000 (equivalent to approximately HK\$62,500,000).

The proposed increase of RMB30,000,000 (equivalent to approximately HK\$37,500,000) in the registered capital of Zhuhai Essex will be contributed by its existing sole shareholder, Essex Bio-Pharmacy, another indirect wholly-owned subsidiary of the Company, by way of allocation of an amount of RMB30,000,000 from the retained earnings of Zhuhai Essex for the year ended 31 December 2011 to its registered capital.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 8 May 2013, resolutions were passed by the board of directors of 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited*) (“**Zhuhai Essex**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, “**Group**”), approving, among other matters, the increase in the total investment of Zhuhai Essex from RMB28,000,000 (equivalent to approximately HK\$35,000,000) to RMB70,000,000 (equivalent to approximately HK\$87,500,000) and the increase in the registered capital of Zhuhai Essex from RMB20,000,000 (equivalent to approximately HK\$25,000,000) to RMB50,000,000 (equivalent to approximately HK\$62,500,000) (collectively, “**Capital Increase**”).

The proposed increase of RMB30,000,000 (equivalent to approximately HK\$37,500,000) in the registered capital of Zhuhai Essex will be contributed by its existing sole shareholder, Essex Bio-Pharmacy Limited (“**Essex Bio-Pharmacy**”), another indirect wholly-owned subsidiary of the Company, by way of allocation of an amount of RMB30,000,000 from the retained earnings of Zhuhai Essex for the year ended 31 December 2011 to its registered capital. The Capital Increase will become effective subject to the approvals from the relevant authorities in the People’s Republic of China (“**PRC**”). Application for such approvals will be made by Zhuhai Essex to the relevant authorities in due course.

As at the date of this announcement, Zhuhai Essex is owned as to 100% by Essex Bio-Pharmacy, which in turn is owned as to 100% by Essex Bio-Investment Limited, a direct wholly-owned subsidiary of the Company. Zhuhai Essex is principally engaged in the manufacturing and selling of biopharmaceutical products.

The directors of the Company (“**Directors**”) believe that the Capital Increase will enable Zhuhai Essex to be more adequately capitalized which allows for flexibility in any future expansion of the operation and production of the Group and will enhance the credit standing of Zhuhai Essex for any future bank financing for the Group. Accordingly, the Directors consider that the Capital Increase is in the interest of the Company and its shareholders as a whole.

For the purpose of this announcement, unless otherwise stated, conversion of RMB into HK\$ is based on the approximate exchange rate of RMB1 to HK\$1.25. The exchange rate is for illustration purpose only and does not constitute a representation that any amounts have been, could have been or may be exchanged at this or any other rates at all.

By order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 8 May 2013

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

* *denotes an English translation of a Chinese name*